about
Classification of brain disease in magnetic resonance images using two-stage local feature fusionAlternative microglial activation is associated with cessation of progressive dopamine neuron loss in mice systemically administered lipopolysaccharide.Treadmill Exercise Prevents Increase of Neuroinflammation Markers Involved in the Dopaminergic Damage of the 6-OHDA Parkinson's Disease Model.Glycoprotein NMB: an Emerging Role in Neurodegenerative Disease.Astrocytic Expression of GSTA4 Is Associated to Dopaminergic Neuroprotection in a Rat 6-OHDA Model of Parkinson's Disease.199 years of Parkinson disease - what have we learned and what is the path to the future?Pimavanserin: A Novel Antipsychotic for Parkinson's Disease Psychosis.Rabs, Membrane Dynamics, and Parkinson's Disease.Potential Modes of Intercellular α-Synuclein Transmission.Sigma-1 (σ1) Receptor in Memory and Neurodegenerative Diseases.Non-human primate models of PD to test novel therapies.Association of Helicobacter pylori infection with Parkinson's diseases: A meta-analysis.Therapeutic implication of autophagy in neurodegenerative diseases.Physical Exercise Modulates L-DOPA-Regulated Molecular Pathways in the MPTP Mouse Model of Parkinson's Disease.The neuroprotective effect of nicotine in Parkinson's disease models is associated with inhibiting PARP-1 and caspase-3 cleavage.A Perspective on Wearable Sensor Measurements and Data Science for Parkinson's Disease.KM-34, a Novel Antioxidant Compound, Protects against 6-Hydroxydopamine-Induced Mitochondrial Damage and Neurotoxicity.Tamoxifen usage correlates with increased risk of Parkinson's disease in older women with breast cancer: a case-control study in Taiwan.Rab10 Phosphorylation Detection by LRRK2 Activity Using SDS-PAGE with a Phosphate-binding Tag.Adverse effects produced by different drugs used in the treatment of Parkinson's disease: A mixed treatment comparison.ExPPNing how acetylcholine improves gait in Parkinson's disease: An Editorial Highlight for 'Deletion of the Vesicular Acetylcholine Transporter from Pedunculopontine/laterodorsal tegmental neurons modifies gait'.Assessments of plasma ghrelin levels in the early stages of parkinson's disease.The role of TGF-β superfamily signaling in neurological disorders.Advanced Parkinson's or "complex phase" Parkinson's disease? Re-evaluation is needed.What is Functional Mobility Applied to Parkinson's Disease?Parkinson's Disease-Associated Mutant LRRK2-Mediated Inhibition of miRNA Activity is Antagonized by TRIM32.Impact of membrane curvature on amyloid aggregation.Glutathione S-Transferase Alpha 4 Prevents Dopamine Neurodegeneration in a Rat Alpha-Synuclein Model of Parkinson's Disease.Clinical aspects of adherence to pharmacotherapy in Parkinson disease: A PRISMA-compliant systematic review.Cardinal Motor Features of Parkinson's Disease Coexist with Peak-Dose Choreic-Type Drug-Induced Dyskinesia.Spatial disorientation and executive dysfunction in elderly nondemented patients with Parkinson's diseaseA Pilot Study to Determine the Consistency of Simultaneous Sleep Actigraphy Measurements Comparing All Four Limbs of Patients with Parkinson Disease
P2860
Q36282942-BA3622DB-38CA-4C7E-8C87-0576035DB669Q38617000-8CC80552-4B27-4035-ACD0-E07CD5C37233Q38628034-C5A04081-B8BF-48F4-B542-BA99B1392EF2Q38693732-43656466-5793-4CAD-9B31-8254B3DCBFB0Q38696005-6A5B6A66-38D3-434F-BE17-DAD221762033Q38825770-0CBFA230-E5AA-47A4-BCA9-645E8EAF57EBQ38856074-39C7A221-49E5-45D6-8D87-22F7D21BD80AQ39031304-F48F7925-10AB-428E-AC02-4BA607A74984Q39152836-4E6AF3F2-33B0-46CE-954B-92743C7D0088Q39169781-22AD351F-DD06-417C-81BB-7D22EEC78E87Q39229450-E582063C-C2D6-4737-B3E3-4066C2B1B9FBQ39361850-5AFC3EE8-FCB6-4EE6-B238-FA64F1857449Q42353908-19B407EA-E316-4F56-AC48-48A0F2A8DECDQ42696309-9EBB6E34-C388-484B-9152-EACD1BDB222AQ47146624-76CBAE04-2F50-47DA-86AD-8241B46CB3E0Q47194371-BD137C50-5B26-42D4-BBFC-60E43882E675Q47237987-892C84BD-993A-43A9-ADC4-2918EFC2C468Q47623516-98AB5AF8-A8CF-4B10-A99C-00CDA4476689Q47891206-F8788A3D-3DAF-4DF7-9A92-10FC4D3C10A6Q48129862-E7F51048-F074-45BD-80B2-A4ED79D07978Q48370307-D270DFAA-E4C7-4E0D-B0C8-11923857E857Q48623727-D1F18895-AE83-49A6-A1BC-A00C921FA705Q49488309-DCE72D52-81C0-4ABE-921A-E3C537917410Q50108912-8711C270-0B99-4A52-AE43-236F8AD02844Q51151114-820EE22B-1BFC-4ED6-B935-4E050CEBFEACQ53741512-4FFFB495-D16E-4F98-BB57-B120587D4071Q54224883-CC4B1A73-4523-41CF-B872-9D79D2907777Q55085565-04AA0AC8-2455-47BB-9D15-97F3F07FF735Q55209544-875CA5A4-859C-443D-8790-12C44BED97CAQ55431534-409EA7C3-AE2C-4C30-AB24-7F0B600FF4BCQ57485185-16E103C1-C883-44D1-BE2A-31345356B14AQ57771071-3D0094D0-D6CE-4EDA-A437-2879F6D562B3
P2860
description
2016 nî lūn-bûn
@nan
2016 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
The clinical symptoms of Parkinson's disease.
@ast
The clinical symptoms of Parkinson's disease.
@en
The clinical symptoms of Parkinson's disease.
@nl
type
label
The clinical symptoms of Parkinson's disease.
@ast
The clinical symptoms of Parkinson's disease.
@en
The clinical symptoms of Parkinson's disease.
@nl
prefLabel
The clinical symptoms of Parkinson's disease.
@ast
The clinical symptoms of Parkinson's disease.
@en
The clinical symptoms of Parkinson's disease.
@nl
P2860
P356
P1476
The clinical symptoms of Parkinson's disease.
@en
P2093
Sigurlaug Sveinbjornsdottir
P2860
P304
P356
10.1111/JNC.13691
P407
P478
139 Suppl 1
P577
2016-07-11T00:00:00Z